Table 1.
Baseline clinical characteristics of patients
| Variables | Group 1, n=78, n (%) | Group 2, n=78, n (%) | P-value |
|---|---|---|---|
| Risk factors for coronary heart disease | |||
| Arterial hypertension | 60 (76.9) | 64 (82.1) | NS |
| Current smoking | 50 (64.1) | 40 (51.3) | NS |
| Family history of ischemic heart disease | 30 (38.5) | 24 (30.8) | NS |
| Family history of T2DM | 8 (10.3) | 16 (20.5) | 0.045 |
| Patient history | |||
| Angina prior to myocardial infarction | 46 (59.0) | 40 (51.3) | NS |
| Previous myocardial infarction | 14 (18.0) | 16 (20.5) | NS |
| History of cerebrovascular accident/transient ischemic attack | 6 (7.7) | 2 (2.6) | NS |
| Comorbidities | |||
| Chronic bronchitis in remission | 8 (10.3) | 4 (5.1) | NS |
| Bronchial asthma | 4 (5.1) | 4 (5.1) | NS |
| Ulcer disease in remission | 4 (5.1) | 6 (7.7) | NS |
| Chronic cholecystitis in remission | 6 (7.7) | 10 (12.8) | NS |
| Characteristics of myocardial infarction | |||
| Q-wave myocardial infarction | 56 (71.8) | 62 (79.5) | NS |
| Non-Q-wave myocardial infarction | 22 (28.2) | 16 (20.5) | NS |
| Localization of myocardial infarction | |||
| Posterior | 44 (56.4) | 40 (51.3) | NS |
| Posterior with extension to the right ventricle | 8 (10.3) | 4 (5.1) | NS |
| Anterior | 26 (33.3) | 32 (41.0) | NS |
| Inferio-posterio-lateral | 0 | 2 (2.6) | |
| Complications of myocardial infarction in-hospital period | |||
| Acute heart failure (Killip classification) | |||
| I | 56 (71.8) | 49(62.8) | NS |
| II | 12 (15.4) | 16(20.5) | NS |
| III | 10 (12.8) | 8 (10.3) | NS |
| IV | 0 | 2 (2.6) | |
| Rhythm disturbance | 26 (33.3) | 22 (28.2) | NS |
| Early postinfarction angina | 8 (5.1) | 12 (10.3) | NS |
| Recurrent myocardial infarction | 2 (2.6) | 0 | |
| Treatment strategy/group of drugs | |||
| Hospital period | |||
| Stenting of the infarct-related artery | 76 (94.8) | 75 (92.3) | NS |
| Systemic thrombolytic therapy | 2 (2.6) | 2 (2.6) | NS |
| β-Blockers | 77 (97.4) | 78 (100.0) | NS |
| Angiotensin-converting enzyme | 70 (89.7) | 68 (87.2) | NS |
| Calcium channel blocker | 62 (79.5) | 62 (79.5) | NS |
| Diuretics | 28 (35.9) | 32 (41.0) | NS |
| Nitrates | 14 (18.0) | 18 (23.1) | NS |
| Aspirin | 77 (97.4) | 78 (100) | NS |
| Heparin | 78 (100) | 78 (100) | NS |
| Clopidogrel | 74 (94.8) | 72 (92.3) | NS |
| Regular intake of drugs in the posthospital period | |||
| β-Blockers | 66 (84.6) | 64 (82.1) | NS |
| Angiotensin-converting enzyme | 56 (71.8) | 60 (76.9) | NS |
| Calcium channel blocker | 36 (46.2) | 42 (53.9) | NS |
| Diuretics | 20 (25.6) | 20 (25.6) | NS |
| Nitrates | 10 (12.8) | 3 (7.7) | NS |
| Aspirin | 74 (94.8) | 68 (87.2) | NS |
| Valsartan | 24 (15.4) | 10 (12.8) | NS |
| Clopidogrel | 76 (92.3) | 75 (89.7) | NS |
| Statins | 78 (100) | 78 (100) |
Notes: Group 1: atorvastatin at a dose of 20 mg/day. Group 2: atorvastatin at a dose of 40 mg/day.
Abbreviations: NS, no statistically significant difference; T2DM, type 2 diabetes mellitus.